drugset / Trial / NCT07222878
Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules Compared to the Original Formulation of NPT 2042
Non-randomizedCrossoverOpen-labelTreatment
Summary
A Single-center, Open-label, Single-dose, Three-period, Fixed Sequence Study to Evaluate the Relative Bioavailability of a New Formulation of NPT 2042 Soft-Gelatin Capsules
Timeline
- Start
- 2025-09-29
- Primary completion
- 2025-11-04
- Completion
- 2025-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | NPT 2042 | Unknown | 80 mg | Oral |